Evidence map›Paper›PMID 33535985›Full record

ArticleBMC neurology2021

The aquaporin4-IgG status and how it affects the clinical features and treatment response in NMOSD patients in Egypt.

Nirmeen A Kishk, Walaa Abdelfattah, Nevin M Shalaby, Hatem S Shehata, Amr Hassan, Mohamed I Hegazy, Noha T Abokrysha, Doaa Abdellatif, Shereen M Shawky, Sarah S Abdo and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nirmeen A KishkDepartment of Neurology, Kasr-Alainy Faculty of Medicine, Cairo University, 7 Emtedad al Ikhaa, Maadi, Nile Corniche, Cairo, Egypt.
Walaa AbdelfattahDepartment of Clinical Pathology, Kasr-Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Nevin M ShalabyDepartment of Neurology, Kasr-Alainy Faculty of Medicine, Cairo University, 7 Emtedad al Ikhaa, Maadi, Nile Corniche, Cairo, Egypt.
Hatem S ShehataDepartment of Neurology, Kasr-Alainy Faculty of Medicine, Cairo University, 7 Emtedad al Ikhaa, Maadi, Nile Corniche, Cairo, Egypt.
Amr HassanDepartment of Neurology, Kasr-Alainy Faculty of Medicine, Cairo University, 7 Emtedad al Ikhaa, Maadi, Nile Corniche, Cairo, Egypt.
Mohamed I HegazyDepartment of Neurology, Kasr-Alainy Faculty of Medicine, Cairo University, 7 Emtedad al Ikhaa, Maadi, Nile Corniche, Cairo, Egypt.
Noha T AbokryshaDepartment of Neurology, Kasr-Alainy Faculty of Medicine, Cairo University, 7 Emtedad al Ikhaa, Maadi, Nile Corniche, Cairo, Egypt.
Doaa AbdellatifDepartment of Neurology, Kasr-Alainy Faculty of Medicine, Cairo University, 7 Emtedad al Ikhaa, Maadi, Nile Corniche, Cairo, Egypt.
Shereen M ShawkyDepartment of Clinical Pathology, Kasr-Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Sarah S AbdoDepartment of Neurology, Kasr-Alainy Faculty of Medicine, Cairo University, 7 Emtedad al Ikhaa, Maadi, Nile Corniche, Cairo, Egypt.
Noha TahaDepartment of Internal Medicine, Kasr-Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Amr M FouadDepartment of Neurology, Kasr-Alainy Faculty of Medicine, Cairo University, 7 Emtedad al Ikhaa, Maadi, Nile Corniche, Cairo, Egypt.
Alaa ElmaznyDepartment of Neurology, Kasr-Alainy Faculty of Medicine, Cairo University, 7 Emtedad al Ikhaa, Maadi, Nile Corniche, Cairo, Egypt.
Amany H RagabDepartment of Neurology, Kasr-Alainy Faculty of Medicine, Cairo University, 7 Emtedad al Ikhaa, Maadi, Nile Corniche, Cairo, Egypt. dr.ahmajd@kasralainy.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Egypt, the characterization of Neuromyelitis Optica Spectrum Disorder (NMOSD) is lacking.

objectivesTo determine the demographics, clinical features, aquaporin4 antibodies (AQP4-IgG) status, and neuroimaging of Egyptian NMOSD patients.

methodsRetrospective analysis of 70 NMOSD patients' records from the MS clinic, Kasr Alainy hospital, between January 2013 and June 2018.

resultsPatients' mean age was 34.9 ± 9.2 years, and the mean at disease onset was 28.9 ± 10.5 years. Fifty-nine patients had an initial monosymptomatic presentation. AQP4-IgG was measured using either enzyme-linked immunosorbent assay (ELISA) (22 patients) or cell-based assay (CBA) (34 patients). Six and 29 patients had positive results, respectively (p < 0.001). 84% had typical NMOSD brain lesions. Longitudinally extensive myelitis was detected in 49 patients, and 9 had either short segments or normal cords. Treatment failure was higher in seropositive patients. Rituximab significantly reduced the annualized relapse rate (ARR) compared to Azathioprine with a percentage reduction of (76.47 ± 13.28) and (10.21 ± 96.07), respectively (p = 0.04). Age at disease onset was the only independent predictor for disability (p < 0.01).

conclusionTreatment failure was higher in seropositive patients. However, there was no difference in clinical or radiological parameters between seropositive and seronegative patients. Patients, who are polysymptomatic or with older age of onset, are predicted to have higher future disability regardless of the AQP4-IgG status.

Indexed as

AdolescentAdultAquaporin 4AutoantibodiesAutoantigensAzathioprineEgyptFemaleHumansImmunologic FactorsImmunosuppressive AgentsMaleMiddle AgedNeuromyelitis OpticaRetrospective StudiesRituximabAQP4 protein, humanAquaporin 4AutoantibodiesAutoantigensAzathioprineImmunologic FactorsImmunosuppressive AgentsRituximabAuaporin4-IgG statusDisabilityNeuromyelitis optica spectrum disorderTreatment response

Identifiers

PMID33535985
PMCPMC7860192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.